WuXi V-Lab App Releases Version 2.0 with New Interface and Payment Feature

We are thrilled to announce the Version 2.0 update of WuXi V-Lab with  a fresh new look with easier viewing and data input, credit card purchasing capability, and improved order tracking.   WuXi...

FDA Approves Ibalizumab Manufactured by WuXi

The FDA has approved the first batch of ibalizumab (TMB-355) drug substance and sterile drug product manufactured at WuXi’s biologics facilities for ongoing treatment of patients in an expanded access program...

WuXi’s STA Subsidiary Opens New Campus in Changzhou

We are pleased to announce that our small-molecule process development and manufacturing subsidiary Shanghai SynTheAll Pharmaceutical Co., Ltd (STA) began operations at a new, fully integrated R&D and cGMP manufacturing site...

WuXi Facility Passes US FDA Inspection for Manufacture of API

We are excited to announce that we have passed a second FDA inspection of our manufacturing facilities.  A manufacturing facility of WuXi's wholly owned subsidiary Shanghai SynTheAll Pharmaceutical Co. Ltd (STA)...

BIO 2018: Going Deep: How AI and Machine Learning Will Transform Drug Discovery

Date: Wednesday, June 6, 2018 Time: 1:45 PM–2:45 PM EST Duration: 1 hour Room: 210C, Level 2 Register here. Overview: While machine learning and artificial intelligence have had a deep impact in solving complex global problems over the...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS

Game Changer: How Genomics and Technology are Transforming Clinical Trials

Advances in genomics are improving elements of drug development, such as design of clinical trial protocols, enrollment of patients and measurement of a potential...